Global Bone Tumor Ablation Devices Market, By Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, and Others), By Indication (Osteosarcoma, Chondrosarcoma, Ewing's Sarcoma, Metastatic Bone Cancer, and Others), By End Users (Hospitals, Outpatient Surgical Centers, and Specialty) Clinics) and by region (North America, Latin America, Europe, Asia-Pacific, Middle East, and Africa), the value is estimated at $56.2 million in 2020 and a CAGR of 10.2% above forecast is expected ( 2020-2027), as highlighted in a new report released by Coherent Market Insights.
This priority list applies to outpatient visits, diagnostics and imaging, surgical oncology, radiation oncology, and medical oncology of primary and metastatic tumors. The increasing number of product approvals, product launches, and cooperation and partnership strategies of the major players are the main factors expected to drive the growth of the Bone Tumor Ablation Devices Market during the forecast period.
The market for bone tumor ablation devices is expected to experience significant growth over the forecast period due to product launches by key players and regulatory approvals. In 2017, Medtronic Plc. received approval from the US Food and Drug Administration (FDA) for an expanded indication of the OsteoCool radiofrequency ablation system for the palliative treatment of metastases throughout the bone anatomy such as the ribs, sacrum, extremities, and hips in patients with failure or are not candidates for standard therapy. The device was originally approved by the USFDA for use on the spine. Medtronic describes the OsteoCool System as a chilled radio frequency (RF) ablation technology with simultaneous dual-probe functions that provide procedural flexibility, predictable and personalized treatment.